Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI in Metastatic Esophageal Carcinoma
NCT02023593Phase 2Completed
- Start
- Mar 2012
- Primary completion
- Dec 2019
- Modality
- Nanoparticles, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil, folinic acid in esophageal carcinoma. Started Mar 2012; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracilfolinic acid
03
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT02023593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023593.